Kensey Nash's smaller puncture closure device gains CE-Mark:
This article was originally published in Clinica
Executive Summary
Kensey Nash has CE-marked a smaller version of its Angio-Seal puncture closure device. The new 6F device will allow the company to address the largest segment of the estimated $1 billion puncture closure market following cardiovascular catheterisation procedures. Approximately 70% of the 6.5 million cardiovascular procedures performed each year are carried out through a 6F or smaller puncture in the femoral artery, said the Exton Pennsylvania-based company.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.